Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other financing activities: 2012-2024

Historic Other financing activities for Amphastar Pharmaceuticals (AMPH) over the last 9 years, with Dec 2024 value amounting to $816,000.

  • Amphastar Pharmaceuticals' Other financing activities fell 99.32% to $4,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $657,000, marking a year-over-year decrease of 50.53%. This contributed to the annual value of $816,000 for FY2024, which is 96.75% down from last year.
  • As of FY2024, Amphastar Pharmaceuticals' Other financing activities stood at $816,000, which was down 96.75% from $25.1 million recorded in FY2023.
  • Amphastar Pharmaceuticals' Other financing activities' 5-year high stood at $25.1 million during FY2023, with a 5-year trough of $407,000 in FY2022.
  • Its 3-year average for Other financing activities is $8.8 million, with a median of $816,000 in 2024.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Other financing activities spiked by 6,061.92% in 2023 and then slumped by 96.75% in 2024.
  • Over the past 4 years, Amphastar Pharmaceuticals' Other financing activities (Yearly) stood at $1.7 million in 2021, then plummeted by 76.58% to $407,000 in 2022, then soared by 6,061.92% to $25.1 million in 2023, then crashed by 96.75% to $816,000 in 2024.